How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,274 results for

Ulcerative Colitis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Ulcerative colitis: management

Ulcerative colitis: management Ulcer Ulcerativ ative colitis: management e colitis: management NICE guideline Published: 3 May 2019 www.nice.org.uk/guidance/ng130 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Ulcerative colitis: management (NG130) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 28Contents Contents Overview 4 Who is it for? 4 Recommendations 5 1.1 Patient information and support 5 1.2

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

2. Ulcerative colitis

Ulcerative colitis Evidence Maps - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3

2018 Trip Evidence Maps

3. Adalimumab (Idacio) - Arthritis, Rheumatoid, Arthritis, Juvenile Rheumatoid, Psoriasis, Arthritis, Psoriatic, Spondylitis, Ankylosing, Uveitis, Hidradenitis Suppurativa, Colitis, Ulcerative, Crohn Disease

Adalimumab (Idacio) - Arthritis, Rheumatoid, Arthritis, Juvenile Rheumatoid, Psoriasis, Arthritis, Psoriatic, Spondylitis, Ankylosing, Uveitis, Hidradenitis Suppurativa, Colitis, Ulcerative, Crohn Disease EMA/85985/2019 EMEA/H/C/004475 Idacio (adalimumab) An overview of Idacio and why it is authorised in the EU What is Idacio and what is it used for? Idacio is a medicine that acts on the immune system (the body’s natural defences) and is used to treat the following conditions: • plaque (...) arthritis (both rare diseases causing inflammation in the joints); • Crohn’s disease (a disease causing inflammation of the gut); • ulcerative colitis (a disease causing inflammation and ulcers in the lining of the gut); • hidradenitis suppurativa (also known as acne inversa, a long-term skin disease that causes lumps, abscesses (collections of pus) and scarring on the skin); • non-infectious uveitis (inflammation of the layer beneath the white of the eyeball). Idacio is mostly used in adults when

2019 European Medicines Agency - EPARs

4. Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. (PubMed)

Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. Endoscopic assessment of mucosal disease activity is routinely used to determine eligibility and response to therapy in clinical trials of ulcerative colitis. The operating properties of the existing endoscopic scoring indices are unclear.A systematic review was undertaken to evaluate the development and operating characteristics of endoscopic scoring indices for the evaluation of ulcerative colitis.We searched (...) MEDLINE, Embase and CENTRAL from inception to 5 July 2016. We also searched references and conference proceedings (Digestive Disease Week, United European Gastroenterology Week, European Crohn's and Colitis Organization).Any study design (e.g. randomized controlled trials, cohort studies, case series) that evaluated endoscopic indices for evaluation of ulcerative colitis disease activity were considered for inclusion. Eligible participants were adult patients (> 16 years), diagnosed with ulcerative

2018 Cochrane

6. Cannabis for the treatment of ulcerative colitis. (PubMed)

Cannabis for the treatment of ulcerative colitis. Cannabis and cannabinoids are often promoted as treatment for many illnesses and are widely used among patients with ulcerative colitis (UC). Few studies have evaluated the use of these agents in UC. Further, cannabis has potential for adverse events and the long-term consequences of cannabis and cannabinoid use in UC are unknown.To assess the efficacy and safety of cannabis and cannabinoids for the treatment of patients with UC.We searched

2018 Cochrane

7. Ulcerative colitis

Ulcerative colitis Ulcerative colitis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Ulcerative colitis Last reviewed: February 2019 Last updated: September 2018 Summary Ulcerative colitis is a type of inflammatory bowel disease characterised by diffuse inflammation of the colonic mucosa and a relapsing, remitting course. Patients commonly experience bloody diarrhoea, chronic diarrhoea (or both), lower abdominal (...) adenocarcinoma is a complication in 3% to 5% of patients. Definition Ulcerative colitis (UC) is a type of inflammatory bowel disease that characteristically involves the rectum and extends proximally to affect a variable length of the colon. It is recognised as a multifactorial polygenic disease, as the exact aetiology is still unknown. Included in the aetiological theories are environmental factors, immune dysfunction, and a likely genetic predisposition. Podolsky DK. Inflammatory bowel disease. N Engl J

2018 BMJ Best Practice

8. Ulcerative colitis

Ulcerative colitis Ulcerative colitis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Ulcerative colitis Last reviewed: February 2019 Last updated: September 2018 Summary Ulcerative colitis is a type of inflammatory bowel disease characterised by diffuse inflammation of the colonic mucosa and a relapsing, remitting course. Patients commonly experience bloody diarrhoea, chronic diarrhoea (or both), lower abdominal (...) adenocarcinoma is a complication in 3% to 5% of patients. Definition Ulcerative colitis (UC) is a type of inflammatory bowel disease that characteristically involves the rectum and extends proximally to affect a variable length of the colon. It is recognised as a multifactorial polygenic disease, as the exact aetiology is still unknown. Included in the aetiological theories are environmental factors, immune dysfunction, and a likely genetic predisposition. Podolsky DK. Inflammatory bowel disease. N Engl J

2018 BMJ Best Practice

9. AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis

AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis - Gastroenterology Email/Username: Password: Remember me Search AGA Journals Search Terms Search within Search Access provided by Volume 156, Issue 3, Pages 748–764 AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis x Cynthia W. Ko Affiliations Division of Gastroenterology (...) Outline Abbreviations used in this paper: ( ), ( ), ( ), ( ), ( ), ( ), ( ), ( ) This document presents the official recommendations of the American Gastroenterological Association (AGA) on the management of mild-to-moderate ulcerative colitis (UC). The guideline was developed by the AGA Institute’s Clinical Guidelines Committee and approved by the AGA Institute Governing Board. It is accompanied by a technical review x 1 Singh, S., Feuerstein, J.D., Binion, D.G. et al. American Gastroenterological

2019 American Gastroenterological Association Institute

10. Histologic scoring indices for evaluation of disease activity in ulcerative colitis. (PubMed)

Histologic scoring indices for evaluation of disease activity in ulcerative colitis. Disease activity can be determined using clinical, endoscopic or histologic criteria in patients with ulcerative colitis (UC). Persistent disease activity is associated with poor outcomes. Histologic disease activity has been shown to be associated with relapse, colectomy and colorectal cancer. The ability to objectively evaluate microscopic disease activity using histology is important for both clinical (...) practice and clinical trials. However, the operating properties of the currently available histologic indices remain unclear.A systematic review was undertaken to identify and evaluate the development and operating characteristics of histologic disease activity indices used to assess disease activity in people with ulcerative colitis.We searched MEDLINE, EMBASE, PubMed, CENTRAL and the Cochrane IBD Review Group Specialized Trials Register from inception to 2 December 2016 for applicable studies

2017 Cochrane

11. DUBLIN (Degree of Ulcerative colitis Burden of Luminal INflammation) score, a simple method to quantify inflammatory burden in Ulcerative Colitis. (PubMed)

DUBLIN (Degree of Ulcerative colitis Burden of Luminal INflammation) score, a simple method to quantify inflammatory burden in Ulcerative Colitis. Endoscopic scores of local severity do not reflect disease extent, or disease burden. The DUBLIN score is a simple bedside clinical score that estimates inflammatory burden using both disease severity and extent. As the need to personalise therapy for UC patients increases, a score to accurately assess disease burden will be of great relevance (...) 2.98 95% CI 1.002-8.87; p=0.049).The DUBLIN score is a simple measure of inflammatory burden which correlates with objective inflammatory markers and is associated with clinical outcomes such treatment failure. DUBLIN score has the potential to assist in personalising therapy for patients with UC.Copyright © 2019 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

2019 Journal of Crohn's & colitis

12. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. (PubMed)

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Maintenance of remission is a major issue in inflammatory bowel disease. In ulcerative colitis, the evidence for the effectiveness of azathioprine and 6-mercaptopurine for the maintenance of remission is still controversial.To assess the effectiveness and safety of azathioprine and 6-mercaptopurine for maintaining remission of ulcerative colitis.The MEDLINE, EMBASE and Cochrane Library databases were searched (...) outcome was failure to maintain clinical or endoscopic remission. Secondary outcomes included adverse events and withdrawal due to adverse events. Analyses were performed separately by type of control (placebo, or active comparator). Pooled risk ratios were calculated based on the fixed-effect model unless heterogeneity was shown. The GRADE approach was used to assess the overall quality of evidence for pooled outcomes.Seven studies including 302 patients with ulcerative colitis were included

Full Text available with Trip Pro

2016 Cochrane

13. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. (PubMed)

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Oral 5-aminosalicylic acid (5-ASA) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) while maintaining its therapeutic benefits. Previously, it was found that 5-ASA drugs in doses of at least 2 g/day, were more effective than placebo but no more effective than SASP for inducing remission in ulcerative colitis. This updated review includes more recent studies and evaluates the efficacy (...) and safety of 5-ASA preparations used for the treatment of mild to moderately active ulcerative colitis.The primary objectives were to assess the efficacy, dose-responsiveness and safety of oral 5-ASA compared to placebo, SASP, or 5-ASA comparators for induction of remission in active ulcerative colitis. A secondary objective of this systematic review was to compare the efficacy and safety of once daily dosing of oral 5-ASA with conventional (two or three times daily) dosing regimens.A computer-assisted

Full Text available with Trip Pro

2016 Cochrane

14. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. (PubMed)

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Oral 5-aminosalicylic (5-ASA) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) while maintaining its therapeutic benefits. Previously, it was found that 5-ASA drugs were more effective than placebo but had a statistically significant therapeutic inferiority relative to SASP. This updated review includes more recent studies and evaluates the effectiveness, dose-responsiveness, and safety (...) of 5-ASA preparations used for maintenance of remission in quiescent ulcerative colitis.The primary objectives were to assess the efficacy, dose-responsiveness and safety of oral 5-ASA compared to placebo, SASP, or 5-ASA comparators for maintenance of remission in quiescent ulcerative colitis. A secondary objective was to compare the efficacy and safety of once daily dosing of oral 5-ASA with conventional (two or three times daily) dosing regimens.A literature search for relevant studies (inception

Full Text available with Trip Pro

2016 Cochrane

15. Two injections are equally effective for treating flare ups of severe ulcerative colitis

Two injections are equally effective for treating flare ups of severe ulcerative colitis Two injections are equally effective for treating flare ups of severe ulcerative colitis Discover Portal Discover Portal Two injections are equally effective for treating flare ups of severe ulcerative colitis Published on 6 September 2016 doi: There is little difference between the newer drug infliximab and the older ciclosporin for treating adults with severe ulcerative colitis that has become resistant (...) to the usual treatment with steroids. Infliximab was more expensive. Ulcerative colitis is a chronic disease where the colon and rectum become inflamed. For severe flare-ups, the standard treatment is steroids. But these do not work for almost a third of patients. In this case, NICE recommend ciclosporin, an immunosuppressant or infliximab, another drug given intravenously in hospital, if ciclosporin is contraindicated. This NIHR-funded trial of 270 adults compared the two drugs over one to three years

2019 NIHR Dissemination Centre

16. Establishment of a Novel Scoring System for Colon Capsule Endoscopy to Assess the Severity of Ulcerative Colitis-Capsule Scoring of Ulcerative Colitis. (PubMed)

Establishment of a Novel Scoring System for Colon Capsule Endoscopy to Assess the Severity of Ulcerative Colitis-Capsule Scoring of Ulcerative Colitis. The usefulness of second-generation colon capsule endoscopy (CCE-2) for ulcerative colitis (UC) has not been fully demonstrated. This study aimed to develop an endoscopic severity score of UC for CCE-2.Patients diagnosed with UC were enrolled prospectively and underwent colonoscopy and CCE-2 on the same day. The collected CCE-2 videos were (...) adopted for the development of the score. These videos were scored by 4 blinded inflammatory bowel disease experts. The items validated with the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) were used as the candidate items, some of which were automatically assessed using the workstation. Each item was divided into proximal and distal parts at the splenic flexure and then individually assessed. The image readers simultaneously evaluated the inflammation severity using the visual analog scale

2018 Inflammatory Bowel Diseases

17. Colonic Mucosal Transcriptomic Changes in Patients with Long-Duration Ulcerative Colitis Revealed Colitis-Associated Cancer Pathways. (PubMed)

Colonic Mucosal Transcriptomic Changes in Patients with Long-Duration Ulcerative Colitis Revealed Colitis-Associated Cancer Pathways. Patients with ulcerative colitis [UC] with long disease duration have a higher risk of developing colitis-associated cancer [CAC] compared with patients with short-duration UC. The aim of this study was to identify transcriptomic differences associated with the duration of UC disease.We conducted transcriptome profiling on 32 colonic biopsies [11 long-duration UC (...) genes exhibited differential alternative splicing between long- and short-duration UC. Among them, 374 were differentially expressed, underscoring the intrinsic relationship between altered gene expression and alternative splicing.Long-duration UC patients have altered gene expressions, pathways, and alternative splicing events as compared with short-duration UC patients, and these could be further validated to improve our understanding of the pathogenesis of CAC.© European Crohn’s and Colitis

Full Text available with Trip Pro

2019 Journal of Crohn's & colitis

18. Alicaforsen for active ulcerative colitis - second line

Alicaforsen for active ulcerative colitis - second line Alicaforsen for active ulcerative colitis – second line Alicaforsen for active ulcerative colitis – second line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Alicaforsen for active ulcerative colitis – second line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre (...) . Horizon Scanning Review. 2016 Authors' objectives Ulcerative colitis is a type of chronic inflammatory bowel disease that causes ulcers on the lining of the large bowel. Patients suffer with pain and diarrhoea and the condition may deteriorate and lead to hospital admissions. Ulcerative colitis can have a large impact on patients' quality of life. Alicaforsen is a new treatment option that may reduce inflammation in the large bowel. It is taken once a day or once every other day as an enema

2016 Health Technology Assessment (HTA) Database.

19. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. (PubMed)

Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. Acute severe colitis (ASC) is one of the few emergencies in pediatric gastroenterology. Tight monitoring and timely medical and surgical interventions may improve outcomes and minimize morbidity and mortality. We aimed to standardize daily treatment (...) of the national representatives of ECCO and all members of the Paediatric Inflammatory Bowel Disease (IBD) Porto group of ESPGHAN (43 voting experts).A total of 24 recommendations and 43 practice points were endorsed with a consensus rate of at least 91% regarding diagnosis, monitoring, and management of ASC in children. A summary flowchart is presented based on daily scoring of the Paediatric Ulcerative Colitis Activity Index. Several topics have been altered since the previous 2011 guidelines and from those

2018 Journal of Pediatric Gastroenterology and Nutrition

20. Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial. (PubMed)

Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial. High-intensity, aerobically prepared fecal microbiota transplantation (FMT) has demonstrated efficacy in treating active ulcerative colitis (UC). FMT protocols involving anaerobic stool processing methods may enhance microbial viability and allow efficacy with a lower treatment intensity.To assess the efficacy of a short duration of FMT therapy to induce remission

2019 JAMA

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>